Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTX-siLIN28B
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TTX-siLIN28B is a small interfering RNA (siRNA) cancer therapeutic candidate developed by TransCode Therapeutics that targets the oncogenic RNA binding protein LIN28B. LIN28B is implicated in tumorigenesis and poor survival outcomes in a variety of cancers, including pancreatic, hepatocellular, colon, lung, multiple myeloma, and neuroblastoma. TTX-siLIN28B utilizes a proprietary nanoparticle delivery platform to deliver siRNA molecules specifically designed to silence LIN28B expression in tumor cells. Preclinical studies have shown that targeting LIN28B with siRNA leads to reduced tumor cell proliferation, induction of cell-cycle arrest, and apoptosis, resulting in potent tumor suppression and inhibition of in vivo tumor xenograft growth. TTX-siLIN28B remains in preclinical development, with an exclusive option agreement for licensing from Massachusetts General Hospital to TransCode Therapeutics[3][1][5][7][8].
- Other names
- TTX-siLIN28BTTX-siLIN-28BTTX-siLIN 28B
02
Targets
LIN28B (Protein lin-28 homolog B)
Beyond the preview
Go deeper on TTX-siLIN28B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTX-siLIN28B.